title: Intracranial mass lesions in acquired immunodeficiency syndrome: using decision analysis to determine the effectiveness of stereotactic brain biopsy.
abstract: We studied the effectiveness of performing a stereotactic brain biopsy in the individual with acquired immunodeficiency syndrome (AIDS) and an intracranial mass lesion who failed 2 weeks of antitoxoplasmosis therapy. We used a decision analysis to compare two different treatment strategies: biopsy and no biopsy. The analysis estimates the average life expectancy for each choice and investigates the sensitivity of these results by varying parameters within the model. In the base case analysis (diagnostic yield of biopsy, 0.89; operative mortality, 0.015; life expectancy of lymphoma untreated and treated, 42 and 120 days), the life expectancy of the biopsy strategy was 98 days compared with 67 days for the no-biopsy strategy, for a net survival benefit of 31 days. Sensitivity analyses revealed that the life expectancy of the biopsy strategy remained greater than the no-biopsy strategy for a wide range of variable specifications. The net survival benefit, however, was sensitive to the diagnostic success rate, the operative mortality, the likelihood of a lymphoma diagnosis, and the life expectancy of patients being diagnosed and treated for lymphoma. These data allow AIDS patients and physicians to learn more about the potential outcomes of the alternative management strategies when an individual fails to respond to empiric antitoxoplasmosis therapy.
authors.affiliation: Department of Neurology, University of Rochester School of Medicine and Dentistry, NY 14642, USA.
authors.forename: R G
authors.initials: RG
authors.lastname: Holloway
authors.forename: A I
authors.initials: AI
authors.lastname: Mushlin
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000150:complications*; D001706:Biopsy / Q000379:methods*; D001921:Brain / Q000473:pathology*; D003661:Decision Support Techniques; D003663:Decision Trees; D005069:Evaluation Studies as Topic; D006801:Humans; D012680:Sensitivity and Specificity; D013238:Stereotaxic Techniques; D016781:Toxoplasmosis, Cerebral / Q000188:drug therapy / Q000209:etiology* / Q000473:pathology*; D017211:Treatment Failure